Research progress in prevention and treatment of radiation-induced intestinal injury by traditional Chinese medicine active components.
10.19540/j.cnki.cjcmm.20230411.602
- Author:
Chuang-Chuang WANG
1
;
Hong-Xin NING
2
;
Hang LI
1
;
Mei-Jing LIANG
1
;
Meng-Yi LI
1
;
Shuai WANG
1
;
Jiang-Hong GUO
2
;
Yi-Liang LI
2
;
Wen-Bin HOU
2
Author Information
1. Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
2. Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences &Peking Union Medical College Tianjin 300192, China.
- Publication Type:Journal Article
- Keywords:
TCM active components;
pathogenesis;
radiation-induced intestinal injury;
research progress
- MeSH:
Medicine, Chinese Traditional;
Drugs, Chinese Herbal/pharmacology*;
Quality of Life;
Intestines;
Alkaloids
- From:
China Journal of Chinese Materia Medica
2023;48(14):3743-3752
- CountryChina
- Language:Chinese
-
Abstract:
Radiation-induced intestinal injury(RIII), a common complication of radiotherapy for pelvic malignancies, affects the quality of life and the radiotherapy efficacy for cancer. Currently, the main clinical approaches for the prevention and treatment of RIII include drug therapy, hyperbaric oxygen therapy, and surgical treatment. Among these methods, drug therapy is cost-effective. Traditional Chinese medicine(TCM) containing a variety of active components demonstrates mild side effects and good efficacy in preventing and treating RIII. Studies have proven that TCM active components, such as flavonoids, terpenoids, phenylpropanoids, and alkaloids, can protect the intestine against RIII by inhibiting oxidative stress, regulating the expression of inflammatory cytokines, modulating the mitochondrial apoptosis pathway, adjusting intestinal flora, and suppressing cell apoptosis. These mechanisms can help alleviate the symptoms of RIII. The paper aims to provide a theoretical reference for the discovery of new drugs for the prevention and treatment of RIII by reviewing the literature on TCM active components in the last 10 years.
